Should I buy or sell Greenwich LifeSciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Greenwich LifeSciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLSI shares. View GLSI analyst ratings or view top-rated stocks .

What is Greenwich LifeSciences' stock price target for 2024?

1 brokerages have issued 12 month price objectives for Greenwich LifeSciences' shares. Their GLSI share price targets range from $36.00 to $36.00. On average, they expect the company's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 160.3% from the stock's current price. View analysts price targets for GLSI or view top-rated stocks among Wall Street analysts .

How have GLSI shares performed in 2024?

Greenwich LifeSciences' stock was trading at $10.52 at the beginning of 2024. Since then, GLSI stock has increased by 31.5% and is now trading at $13.83. View the best growth stocks for 2024 here .

When is Greenwich LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our GLSI earnings forecast .

How were Greenwich LifeSciences' earnings last quarter?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) posted its quarterly earnings data on Monday, April, 15th. The company reported ($0.21) EPS for the quarter.

When did Greenwich LifeSciences IPO?

Greenwich LifeSciences (GLSI) raised $7 million in an initial public offering on Friday, September 25th 2020. The company issued 1,300,000 shares at a price of $5.75 per share. Aegis Capital acted as the underwriter for the IPO.

Who are Greenwich LifeSciences' major shareholders?

Greenwich LifeSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.73%). Insiders that own company stock include David Mcwilliams , Frank Joseph Daugherty , Jaye Thompson , Kenneth Hallock and Snehal Patel . View institutional ownership trends .

How do I buy shares of Greenwich LifeSciences?

Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GLSI

Greenwich LifeSciences (GLSI) Stock Price, News & Analysis

→ This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad)

Free GLSI Stock Alerts

$13.28

-0.70 (-5.01%)

(As of 11:23 AM ET)

Compare

Today's Range: $13.10
▼
$13.94
50-Day Range: $12.07
▼
$20.32
52-Week Range: $7.58
▼
$21.44

Volume: 12,308 shs
Average Volume: 42,284 shs
Market Capitalization: $171.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.00

Greenwich LifeSciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 160.3% Upside
$36.00 Price Target
Short Interest: Healthy
3.24% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$187,133 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.60 out of 5 stars

Medical Sector

455th out of 918 stocks

Pharmaceutical Preparations Industry

208th out of 429 stocks

3.5

Analyst's Opinion

Consensus Rating
Greenwich LifeSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Greenwich LifeSciences has only been the subject of 1 research reports in the past 90 days.
Read more about Greenwich LifeSciences' stock forecast and price target.

3.0

Short Interest

Percentage of Shares Shorted
3.24% of the float of Greenwich LifeSciences has been sold short.
Short Interest Ratio / Days to Cover
Greenwich LifeSciences has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Greenwich LifeSciences has recently increased by 2.16%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Greenwich LifeSciences does not currently pay a dividend.
Dividend Growth
Greenwich LifeSciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GLSI.

2.6

News and Social Media Coverage

News Sentiment
Greenwich LifeSciences has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Greenwich LifeSciences this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for GLSI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Greenwich LifeSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $187,133.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
52.86% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 4.16% of the stock of Greenwich LifeSciences is held by institutions.
Read more about Greenwich LifeSciences' insider trading history.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Greenwich LifeSciences is -19.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Greenwich LifeSciences is -19.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Greenwich LifeSciences has a P/B Ratio of 26.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about Greenwich LifeSciences' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

What President Biden's new law means for investors

What's Got Musk, Bezos, and Gates So Excited? Billionaires are plowing millions of dollars into a new technology that early estimates say could generate more wealth than A.I. – and determine the future of companies like Microsoft. The problem? Most investors have no idea it's happening, or how to profit on it.

This expert just went public with all the details, including which stocks to jump on immediately.

About Greenwich LifeSciences Stock (NASDAQ:GLSI)

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

GLSI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GLSI Stock News Headlines

May 17 at 2:38 AM | americanbankingnews.com

Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 2%

April 15, 2024 | markets.businessinsider.com

GLSI Stock Earnings: Greenwich LifeSciences Misses EPS for Q4 2023

March 13, 2024 | globenewswire.com

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

March 12, 2024 | globenewswire.com

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

March 7, 2024 | finance.yahoo.com

Greenwich LifeSciences Inc (GLSI) CEO and CFO, 10% Owner Snehal Patel Acquires Additional Shares

February 28, 2024 | markets.businessinsider.com

Expanding Horizons: Bullish Buy Rating as Greenwich LifeSciences’s Breast Cancer Trial Goes Pan-European

February 27, 2024 | msn.com

Greenwich LifeSciences stock jumps 8% on Phase 3 study expansion

February 27, 2024 | finanznachrichten.de

Greenwich LifeSciences, Inc.: Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

February 27, 2024 | globenewswire.com

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

February 23, 2024 | benzinga.com

Greenwich LifeSciences Stock (NASDAQ:GLSI) Dividends: History, Yield and Dates

February 22, 2024 | finanznachrichten.de

Greenwich LifeSciences, Inc.: Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

February 22, 2024 | msn.com

Greenwich Lifesciences announces acceptance for Flamingo-01 trial by EMA

February 22, 2024 | finance.yahoo.com

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

February 22, 2024 | globenewswire.com

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

February 21, 2024 | realmoney.thestreet.com

2 Rare Insider Buys in a Frothy Market

February 20, 2024 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for Greenwich LifeSciences: Here's What You Need To Know

February 14, 2024 | msn.com

Why Greenwich Lifesciences (GLSI) Stock Is Skyrocketing

February 14, 2024 | morningstar.com

Greenwich LifeSciences Shares Rise as Company Prepares FDA Filing for Breast Cancer Immunotherapy

February 14, 2024 | globenewswire.com

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

December 21, 2023 | bbc.co.uk

Greenwich: Closed pub reopens as community hub

December 11, 2023 | finance.yahoo.com

Insiders hold 54% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), and they've been buying recently

December 2, 2023 | yahoo.com

Greenwich, United States - Weather Forecasts | Maps | News - Yahoo Weather

November 21, 2023 | finanznachrichten.de

Greenwich LifeSciences, Inc.: Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

November 21, 2023 | finance.yahoo.com

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

November 14, 2023 | finance.yahoo.com

Greenwich LifeSciences Insiders Added US$653.7k Of Stock To Their Holdings

See More Headlines

Company Calendar

Last Earnings: 4/15/2024
Today: 5/20/2024
Next Earnings (Estimated): 5/27/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GLSI
CUSIP: N/A
CIK: 1799788
Web: www.greenwichlifesciences.com
Phone: 832-819-3232
Fax: N/A
Employees: 3
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $36.00
High Stock Price Target: $36.00
Low Stock Price Target: $36.00
Potential Upside/Downside: +157.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,890,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -93.88%
Return on Assets: -91.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 23.77
Quick Ratio: 23.77

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.52 per share
Price / Book: 26.88

Miscellaneous

Outstanding Shares: 12,880,000
Free Float: 6,071,000
Market Cap: $180.06 million
Optionable: Not Optionable
Beta: 1.55

Key Executives

Mr. Snehal S. Patel (Age 60)
CEO, CFO & Director
Comp: $1.09M
Mr. Eric Rothe (Age 48)
Founder & Independent Director
Comp: $65.64k
Dr. Frank Joseph Daugherty M.D. (Age 73)
Chief Medical Officer & Director
Dr. Jaye L. Thompson Ph.D. (Age 58)
Vice President Clinical & Regulatory Affairs
Dr. Christine T. Fischette Ph.D. (Age 73)
VP of Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GLSI Stock Analysis - Frequently Asked Questions

Should I buy or sell Greenwich LifeSciences stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Greenwich LifeSciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLSI shares.
View GLSI analyst ratings or view top-rated stocks.
What is Greenwich LifeSciences' stock price target for 2024?: 1 brokerages have issued 12 month price objectives for Greenwich LifeSciences' shares. Their GLSI share price targets range from $36.00 to $36.00. On average, they expect the company's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 160.3% from the stock's current price.
View analysts price targets for GLSI or view top-rated stocks among Wall Street analysts.
How have GLSI shares performed in 2024?: Greenwich LifeSciences' stock was trading at $10.52 at the beginning of 2024. Since then, GLSI stock has increased by 31.5% and is now trading at $13.83.
View the best growth stocks for 2024 here.
When is Greenwich LifeSciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024.
View our GLSI earnings forecast.

How were Greenwich LifeSciences' earnings last quarter?: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) posted its quarterly earnings data on Monday, April, 15th. The company reported ($0.21) EPS for the quarter.
When did Greenwich LifeSciences IPO?: Greenwich LifeSciences (GLSI) raised $7 million in an initial public offering on Friday, September 25th 2020. The company issued 1,300,000 shares at a price of $5.75 per share. Aegis Capital acted as the underwriter for the IPO.
Who are Greenwich LifeSciences' major shareholders?: Greenwich LifeSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.73%). Insiders that own company stock include David Mcwilliams, Frank Joseph Daugherty, Jaye Thompson, Kenneth Hallock and Snehal Patel.
View institutional ownership trends.
How do I buy shares of Greenwich LifeSciences?: Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLSI) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Greenwich LifeSciences (GLSI) Stock Price, News & Analysis

Greenwich LifeSciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest